Demethoxycurcumin Inhibits Energy Metabolic and Oncogenic Signaling Pathways through AMPK Activation in Triple-Negative Breast Cancer Cells
Authors:
- 18 June 2013
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 61 (26) , 6366-6375
Abstract
Demethoxycurcumin (DMC), curcumin (Cur), and bisdemethoxycurcumin (BDMC) are major forms of curcuminoids found in the rhizomes of turmeric. This study examined the effects of three curcuminoid analogues on breast cancer cells. The results revealed that DMC demonstrated the most potent cytotoxic effects on breast cancer MDA-MB-231 cells. Compared with estrogen receptor (ER)-positive or HER2-overexpressing breast cancer cells, DMC demonstrated the most efficient cytotoxic effects on triple-negative breast cancer (TNBC) cells. However, nonmalignant MCF-10A cells were unaffected by DMC treatment. The study showed that DMC activated AMPK in TNBC cells. Once activated, AMPK inhibited eukaryotic initiation factor 4E-binding protein-1 (4E-BP1) signaling and mRNA translation via mammalian target of rapamycin (mTOR) and decreased the activity and/or expression of lipogenic enzymes, such as fatty acid synthase (FASN) and acetyl-CoA carboxylase (ACC). DMC also targeted multiple AMPK downstream pathways. Among these, the dephosphorylation of Akt is noteworthy because it circumvents the feedback activation of Akt that results from mTOR inhibition. Moreover, DMC suppressed LPS-induced IL-6 production, thereby blocking subsequent Stat3 activation. In addition, DMC also sustained epidermal growth factor receptor (EGFR) activation by suppressing the phosphatases, PP2a and SHP-2. These results suggest that DMC is a potent AMPK activator that acts through a broad spectrum of anti-TNBC activities.Keywords
This publication has 36 references indexed in Scilit:
- Triple-negative breast cancer: are we making headway at least?Therapeutic Advances in Medical Oncology, 2012
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJournal of Clinical Investigation, 2011
- Pushing the Envelope in the mTOR Pathway: The Second Generation of InhibitorsMolecular Cancer Therapeutics, 2011
- Protection of Trabecular Bone in Ovariectomized Rats by Turmeric (Curcuma longa L.) Is Dependent on Extract CompositionJournal of Agricultural and Food Chemistry, 2010
- Histological evaluation of AMPK signalling in primary breast cancerBMC Cancer, 2009
- The LKB1–AMPK pathway: metabolism and growth control in tumour suppressionNature Reviews Cancer, 2009
- Inflammation and Cancer: IL-6 and STAT3 Complete the LinkCancer Cell, 2009
- EGFR associated expression profiles vary with breast tumor subtypeBMC Genomics, 2007
- Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancerBreast Cancer Research, 2007
- Current development of mTOR inhibitors as anticancer agentsNature Reviews Drug Discovery, 2006